NCT01370148View on ClinicalTrials.gov

A Study to Assess the Effect of Severe Hepatic Impairment on the Pharmacokinetics of Intravenous Conivaptan

PHASE1CompletedINTERVENTIONAL
Enrollment

17

Participants

Timeline

Start Date

April 30, 2011

Primary Completion Date

February 28, 2014

Study Completion Date

February 28, 2014

Conditions
Liver Disease
Interventions
DRUG

conivaptan hydrochloride

Intravenous

Trial Locations (3)

32809

Orlando Clinical Research, Orlando

80228

DaVita Clinical Research, Lakewood

92801

Advanced Clinical Research Institute, Anaheim

Sponsors
All Listed Sponsors
lead

Cumberland Pharmaceuticals

INDUSTRY

NCT01370148 - A Study to Assess the Effect of Severe Hepatic Impairment on the Pharmacokinetics of Intravenous Conivaptan | Biotech Hunter | Biotech Hunter